The Latin America, Middle East and Africa BNP and NT-proBNP Market would witness market growth of 17.9% CAGR during the forecast period (2022-2028).
BNP & NTproBNP measurements can be employed to track the development of the condition and foretell hospitalization risk in people with heart failure. Testing for BNP & NTproBNP is a crucial tool in evaluating and treating many heart disorders. Due to a sizable population of customers who are concerned about their health, the medical device sector is growing and innovating to produce sophisticated diagnostic and biomarker tests, which presents a chance for the BNP & NTproBNP market analysis.
Inactivity, bad eating habits, increased tobacco use, and rising cigarette usage among young people have all increased the risk of strokes, heart attacks, and other CVD issues. As a result, it is primarily responsible for the worldwide disease burden in low- and middle-income nations. Additionally, the increasing use of point-of-care assays, which have advantages over traditional laboratory tests like remote monitoring, shorter hospital stays, higher user experience & patient satisfaction, easier sample collection, and higher accuracy, has a positive impact on the market's expansion.
Furthermore, due to the benefits of high precision and accuracy, minimal pain, and quick diagnosis compared to conventional methods, non-invasive diagnostic procedures are becoming increasingly popular among clinicians. Also driving the market growth are rising government initiatives to expand the accessibility of telemedicine, point-of-care testing, and leading market players concentrating on creating technologically cutting-edge point-of-care testing solutions for cardiovascular diseases.
The majority of countries in the Arabian Middle East are struggling greatly with coronary heart disease (CHD). For instance, in Iraq, Jordan, as well as Syria, CHD is the primary underlying problem of all fatalities. In addition, a high frequency of cardiometabolic risk markers, a lack of patience as well as physician education, infrastructure, and financial constraints lead to a chain of cardiorenal complications (CRCs) occurring at a noticeably younger age. Over the past ten years, the healthcare industry has become one of the GCC's most significant sectors for encouraging economic diversification. This supports the growth of the regional market
The Brazil market dominated the LAMEA BNP and NT-proBNP Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $47.4 Million by 2028. The Argentina market is exhibiting a CAGR of 18.5% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 17.5% during (2022 - 2028).
Based on Location of Testing, the market is segmented into Point of Care Testing and Laboratory Testing. Based on Application, the market is segmented into Myocardial Infarction, Acute Coronary Syndrome (ACS), Congestive Heart Failure (CHF) and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide BNP and NT-proBNP Market is Projected to reach USD 2.2 Billion by 2028, at a CAGR of 11.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Siemens AG, Danaher Corporation, Gentian Diagnostics ASA, PerkinElmer, Inc., BioMérieux S.A., Quidel Corporation, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd. (Roche Holding Ltd.), and Scripps Laboratories.
By Location of Testing
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 